Elizabeth Yeu Lin
Elizabeth Yeu Lin's purchase track record
How the stock did after each of Elizabeth Yeu Lin's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/21/2023 | STAA | $100K | -18.2% | -1.0% | +21.1% |
| 8/15/2023 | TARS | $160K | +5.4% | +74.4% | +11.6% |
| 9/14/2022 | TARS | $297K | -7.9% | -15.6% | -1.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
STAAR Surgical Names New VP, Faces High Valuation Questions. STAAR Surgical appointed Andrew Pilon as Vice President of Business Development. Recent articles discuss whether the stock is undervalued or risky, noting its high trailing P/E of 283.5. The stock is currently trading near a key support level, with analyst targets ranging from $19.00 to $37.00.
Transaction History
| TARS | ▼ Sell | Open Market | 5,387 | $431K | 9/2/2026 | View on chart |
| TARS | ▼ Sell | Open Market | 1,590 | $127K | 9/2/2026 | View on chart |
| TARS | ▼ Sell | Open Market | 4,601 | $340K | 9/1/2026 | View on chart |
| TARS | ▼ Sell | Open Market | 390 | $26K | 3/19/2026 | View on chart |
| TARS | ▼ Sell | Open Market | 379 | $26K | 3/18/2026 | View on chart |
| TARS | ▼ Sell | Open Market | 375 | $26K | 3/17/2026 | View on chart |
| TARS | ▲ Buy | Option Exercise | 2,511 | — | 3/15/2026 | View on chart |
| TARS | ▼ Sell | Open Market | 2,078 | $165K | 12/16/2025 | View on chart |
| TARS | ▲ Buy | Option Exercise | 6,819 | — | 12/15/2025 | View on chart |
| TARS | ▼ Sell | Open Market | 1,006 | $41K | 6/16/2025 | View on chart |
| TARS | ▲ Buy | Option Exercise | 3,350 | — | 6/13/2025 | View on chart |
| TARS | ▲ Buy | Option Exercise | 3,350 | — | 6/24/2024 | View on chart |
| STAA | ▲ Buy | Grant | 2,244 | $0 | 6/20/2024 | View on chart |
| STAA | ▲ Buy | Open Market | 2,500 | $100K | 9/21/2023 | View on chart |
| TARS | ▲ Buy | Open Market | 9,506 | $160K | 8/15/2023 | View on chart |
| TARS | ▲ Buy | Option Exercise | 2,000 | — | 6/16/2023 | View on chart |
| TARS | ▲ Buy | Open Market | 12,040 | $193K | 9/14/2022 | View on chart |
| TARS | ▲ Buy | Open Market | 6,360 | $104K | 9/14/2022 | View on chart |
| STAA | ▲ Buy | Option Exercise | 355 | $0 | 6/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Tarsus Reports XDEMVY Revenue and Option‑Style Retina Deals
The article notes that Tarsus’s drug XDEMVY is now generating revenue to cover operating costs. It also explains that the company’s retina product deals are structured like options, potentially providing flexible upside. These developments may improve the company’s cash flow outlook and support future growth initiatives.
Tarsus Reports XDEMVY Revenue and Option‑Style Retina Deals. The article notes that Tarsus’s drug XDEMVY is now generating revenue to cover operating costs. It also explains that the company’s retina product deals are structured like options, potentially providing flexible upside. These developments may improve the company’s cash flow outlook and support future growth initiatives.